Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,497.7
-3.1 (-0.12%)

 

  • STI Straits Times Index
    2,497.7
    -3.1 (-0.12%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,506.6
    -6.4 (-0.43%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,455.4
    114.6 (0.47%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,338.1
    67.7 (2.07%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,360.3
    40.9 (0.18%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,059.2
    20.8 (0.41%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,595.1M
  • Value: 1,877.8M
  • Rise: 152
  • Fall: 154
  • Unch: 475

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.157-0.008
Oceanus^0.007-
Frasers L&C Tr1.420+0.010
NetLink NBN Tr0.965-0.010
Jiutian Chemical0.045-
Alset0.063+0.002
Rex Intl0.156+0.003
HPH Trust USD0.132+0.007
Golden Agri-Res0.141-0.001
Medtecs Intl1.070-0.110

World Indices

World Indices
Name Last Change
Nasdaq 10,793.3 -117.0
HSI 24,455.4 +114.6
HSCEI 9,803.1 +71.0
Jakarta 5,059.2 +20.8
Nikkei 225 23,360.3 +40.9
SSE Comp 3,338.1 +67.7
Shanghai A 3,498.5 +71.0
Shanghai B 251.8 +1.7
KOSPI 2,412.4 +6.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ROYALTY PHARMA PLC ROYALTY PHARMA PLC CLASS A
Updated on 18 Sep 2020 (End of trading day)
Last (USD): 41.980 Change: +0.700 High: 43.190 Remarks: -
Change (%): +1.70 Low: 41.130
Open 41.280 Yesterday's Close 41.279999999999994
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 5,872,391 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 3.86841 Trailing EPS (USD) e 3.86841 NAV (USD) b 6.8475
PE a 10.852 Trailing PE f 10.852 Price / NAV b 6.1307
Dividend (USD) d - Cash In Hand (USD) g 4.0247 Issued & Paid-up Shares c 365,899,000
Dividend Yield (%) d - Price / Cash In Hand g 10.431 Treasury Shares h -
Market Cap (M) 25,486.310 Enterprise Value (M) 33,820.378
Piotroski F Score 5 Exchange Code RPRX Par Value ( $ ) n.a.
52 Weeks Volatility (%) 429.96 Free Float (%) 78.9
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 12 Aug 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 10 Jul 2020.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ROYALTY PHARMA PLC NASDAQ 25,486.310 10.852 10.852 6.1307 -
Industry Pharmaceuticals: Major NASDAQ 1,764.977 114.250 47.925 2.7526 0.007
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 132,037.103 40.581 10.750 1.8571 2.229
Local Peer CUREVAC NV NASDAQ 9,270.353 - - -193.4993 -
Local Peer REPLIGEN CORP NASDAQ 7,664.855 357.985 247.741 6.9679 -
Local Peer HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS NASDAQ 4,870.418 - - 14.2359 -
Local Peer GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 NASDAQ 4,224.628 6.038 6.863 0.7011 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 4,224.192 - - 10.5343 -
Local Peer ALLAKOS INC NASDAQ 4,114.620 - - 9.2049 -
Local Peer TURNING POINT THERAPEUTICS INC NASDAQ 3,734.899 - - 5.2543 -
Local Peer NEKTAR THERAPEUTICS NASDAQ 3,608.413 - - 2.8724 -
Local Peer REATA PHARMACEUTICALS INC NASDAQ 3,546.312 - - 15.3104 -
Local Peer PRINCIPIA BIOPHARMA INC NASDAQ 3,329.816 - - 9.4748 -
Local Peer I MAB SPON ADS EACH REP 2.3 ORD SHS NASDAQ 2,584.372 - - 10.7297 -
Other Local Peers IGM BIOSCIENCES INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), GENERATION BIO CO (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), PETIQ INC (NASDAQ), ANNEXON INC (NASDAQ), PROVENTION BIO INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), AC IMMUNE SA (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), TRICIDA INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), BEYONDSPRING INC (NASDAQ), IMARA INC (NASDAQ), 89BIO INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), IMMUNIC INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), DURECT CORP (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), MUSTANG BIO INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), ESSA PHARMA INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), VERU INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), HARROW HEALTH INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), EVOLUS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), MEDIWOUND LTD (NASDAQ), EYENOVIA INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 10 ORD SHS (R/S) (NASDAQ), NOVAN INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), PAINREFORM LTD (NASDAQ), PROPHASE LABS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), MANNATECH INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), SUN BIOPHARMA INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), ENTERA BIO LTD (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), NOVUS THERAPEUTICS INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ)
Global Peer JOHNSON & JOHNSON NYSE 392,764.088 25.978 25.865 6.2365 2.513
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 224,354.436 31.831 31.082 4.1692 2.026
Global Peer MERCK & CO INC NYSE 217,034.084 22.050 20.711 7.8516 2.644
Global Peer PFIZER INC NYSE 203,548.514 12.509 14.365 3.1638 3.969
Global Peer ABBVIE INC NYSE 159,028.831 20.279 23.041 10.8125 4.083
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 148,157.541 110.522 68.824 12.1072 2.427
Global Peer ELI LILLY AND COMPANY NYSE 147,458.980 31.794 26.247 36.0278 1.675
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 133,590.431 38.846 - 2.7211 2.802
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 125,864.166 21.555 20.521 13.9080 1.638
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 98,490.777 16.621 15.405 5.8641 4.968
Other Global Peers TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), SINOPHARM (HKEx), JUNSHI BIO (HKEx), SH PHARMA (HKEx), HYGEIA HEALTH (HKEx), BAIYUNSHAN PH (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), HENLIUS-B (HKEx), CHINARES PHARMA (HKEx), CHINAGRANDPHARM (HKEx), ADC THERAPEUTICS SA (NYSE), AKESO-B (HKEx), CMS (HKEx), HEPALINK (HKEx), TRAD CHI MED (HKEx), ZYMEWORKS INC (NYSE), UNITED LAB (HKEx), INNOCARE-B (HKEx), OCUMENSION-B (HKEx), SSY GROUP (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), CKLIFE SCIENCES (HKEx), Kimia Farma Tbk. (IDX), CSTONE PHARMA-B (HKEx), Soho Global Health Tbk. (IDX), TONGRENTANGCM (HKEx), IMMUNOTECH-B (HKEx), HUA MEDICINE-B (HKEx), IGBB (Bursa), SHINEWAY PHARM (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), STARPHARMA HOLDINGS LIMITED (ASX), FUSEN PHARM (HKEx), AFT PHARMACEUTICALS LTD (ASX), PYC THERAPEUTICS LIMITED (ASX), BSTEAD (Bursa), TOT BIOPHARM-B (HKEx), PHARMA (Bursa), LANNETT CO INC (NYSE), ZHONGZHIPHARM (HKEx), DAWNRAYS PHARMA (HKEx), RECCE PHARMACEUTICALS LTD (ASX), CH BIOTECH SER (HKEx), BIOMX INC (NYSE American), KOTRA (Bursa), IX Biopharma (SGX), Merck Tbk. (IDX), NEW RAY MEDIC (HKEx), Hyphens Pharma (SGX), Phapros Tbk. (IDX), NEP INTERLONG (HKEx), ONCOSIL MEDICAL LIMITED (ASX), IP (SET), PAK FAH YEOW (HKEx), NOVA (Bursa), RACE ONCOLOGY LTD (ASX), BIOHLDG (Bursa), PALLA PHARMA LTD (ASX), CHARMACY PHAR (HKEx), NC HEALTHCARE (HKEx), NOXOPHARM LTD (ASX), WAI YUEN TONG (HKEx), IMMURON LIMITED (ASX), TBG DIAGNOSTICS LTD (ASX), INVION LTD (ASX), PURAPHARM (HKEx), ANNOVIS BIO INC (NYSE American), MEDLAB CLINICAL LIMITED (ASX), SANAI HEALTH GP (HKEx), AGEX THERAPEUTICS INC (NYSE American), JCT (SET), EXTRAWELL PHAR (HKEx), EXOPHARM LTD (ASX), PHARMAXIS (ASX), SUNZEN (Bursa), ACRUX (ASX), FIJI KAVA LTD (ASX), SINOLIFE UTD (HKEx), PASHUN INT'L (HKEx), TALI DIGITAL LIMITED (ASX), TIMBER PHARMACEUTICALS INC (NYSE American), SUDA PHARMACEUTICALS LTD (ASX), CRESO PHARMA LTD (ASX), CELLMID LIMITED (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+3.420
+8.87 %
10 Days -+2.200
+5.53 %
20 Days -+0.010
+0.02 %
Medium Term Return 3 Months --7.020
-14.33 %
6 Months -+41.310
+6165.67 %
1 Year -+41.310
+6165.67 %
Long Term Return 2 Years -+41.310
+6165.67 %
3 Years -+41.679
+13846.84 %
5 Years -+33.730
+408.85 %
Annualised Return Annualised --
+38.46 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 38.540 - 56.500 Change From 1 Year Low +3.440 % Change From 1 Year Low (%) +8.93
Change From 1 Year High -14.520 % Change From 1 Year High (%) -25.70
2 Years Range 38.540 - 56.500 Change From 2 Years Low +3.440 % Change From 2 Years Low (%) +8.93
Change From 2 Years High -14.520 % Change From 2 Years High (%) -25.70
5 Years Range 0.260 - 56.500 Change From 5 Years Low +41.720 % Change From 5 Years Low (%) +16046.15
Change From 5 Years High -14.520 % Change From 5 Years High (%) -25.70
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
18 Sep 2020 41.280 43.190 41.130 41.980 5,872,391 -
17 Sep 2020 39.800 41.290 39.720 41.280 1,224,394 -
16 Sep 2020 40.560 40.810 39.740 40.610 751,994 -
15 Sep 2020 40.150 41.220 40.150 40.705 889,155 -
14 Sep 2020 39.100 40.490 38.810 39.820 1,216,756 -
11 Sep 2020 39.560 39.990 38.540 38.560 559,470 -
10 Sep 2020 38.930 40.090 38.930 39.440 886,566 -
09 Sep 2020 39.310 40.490 38.800 38.840 619,283 -
08 Sep 2020 39.800 39.826 38.700 39.040 778,786 -
04 Sep 2020 40.360 40.500 38.910 39.780 1,088,929 -
03 Sep 2020 41.800 41.970 40.400 40.740 819,072 -
02 Sep 2020 41.750 41.950 41.240 41.750 470,384 -
01 Sep 2020 41.700 42.050 41.000 41.600 793,459 -
31 Aug 2020 42.250 42.980 41.200 41.380 946,308 -
28 Aug 2020 41.120 42.450 41.100 42.070 866,784 -
27 Aug 2020 42.120 42.160 40.990 41.000 623,046 -
26 Aug 2020 41.746 42.300 41.550 41.940 602,328 -
25 Aug 2020 42.600 42.730 41.180 41.780 842,293 -
24 Aug 2020 42.470 42.920 41.800 42.730 771,708 -
21 Aug 2020 43.000 43.490 41.510 41.970 918,400 -
20 Aug 2020 44.000 44.380 43.150 43.260 579,305 -
19 Aug 2020 44.640 45.340 43.770 43.900 618,761 -
Summary
Current 2 Weeks
(04 Sep 2020 to 18 Sep 2020)
40.360 43.190 38.540 41.980 13,887,724 -
Previous 2 Weeks
(21 Aug 2020 to 03 Sep 2020)
43.000 43.490 38.540 40.740 7,653,782 -
4 Weeks from
(24 Jul 2020 to 20 Aug 2020)
42.320 43.190 38.540 43.260 17,558,545 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.